RAPT Therapeutics, Inc. plans to report topline data from the Phase 2 clinical trial of RPT904 in patients with Chronic Spontaneous Urticaria on October 20, 2025. The webcast conference call will be held at 8:30 a.m. ET, where participants can join via phone and engage in a live Q&A session. RAPT is a biopharmaceutical company focused on developing novel therapies for inflammatory and immunological diseases. The press release contains forward-looking statements regarding the development of RPT904, regulatory interactions, and potential risks and uncertainties. For more information, visit RAPT Therapeutics’ website or contact the Investor or Media Relations departments.

Read more at GlobeNewswire: RAPT Therapeutics to Report Topline Data from Phase 2